Fundraising Fox

Renibus Therapeutics

Southlake, US · Founded 2015 · Delaware corporation

Biotech

Founders & leadership

JD
Jamie DonadioinExecutive
BS
Bhupinder SinghinExecutive
DJ
D. Jeffrey KeyserExecutive
HK
Harpreet KaurChairman of the Board, Chief Executive Officer and President
NB
Nels BergmarkTreasurer

Board

CG
Carlos GuillemBoard director
HR
Henrik RasmussenBoard director
JK
Jocelyn KeyserBoard director
JD
Jennifer D. RasmussenBoard director
DJ
Dale JonesBoard director

Funding

SEC filings, press & company announcements

$180.1M disclosed across 5 of 6 rounds · 2016–2023

▶$110.9MraisedJul 2025 · 59 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jamie DonadioExecutive Officer
  • Bhupinder SinghExecutive Officer, Director
  • Carlos GuillemDirector
  • D. Jeffrey KeyserExecutive Officer, Director
  • Henrik RasmussenDirector
Offering amount
$110.9M
Amount sold
$110.9M
Finders' fees
$148.3K
Placement agents
Salem Partners LLC
First sale
May 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23.4MraisedAug 2022 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Carlos GuillemDirector
  • Jamie DonadioExecutive Officer
  • Henrik RasmussenDirector
  • D. Jeffrey KeyserExecutive Officer, Director
  • Frank StonebanksExecutive Officer, Director
  • Bhupinder SinghExecutive Officer, Director
Offering amount
$25M
Amount sold
$23.4M
Sales commissions
$12K
Placement agents
Melior Capital Management GMBH
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$34.6MraisedFeb 2022 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Henrik RasmussenDirector
  • Bhupinder SinghDirector
  • Frank StonebanksExecutive Officer, Director
  • D. Jeffrey KeyserExecutive Officer, Director
  • Alvaro GuillemDirector
Offering amount
$34.6M
Amount sold
$34.6M
Sales commissions
$116.6K
Placement agents
Melior Capital Management GMBH
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.9MraisedMay 2016 · 112 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jennifer D. RasmussenDirector
  • Harpreet KaurExecutive Officer, Director
  • Nels BergmarkExecutive Officer
  • Carlos GuillemExecutive Officer, Director
  • Jocelyn KeyserDirector
  • Dale JonesDirector
Offering amount
$12.5M
Amount sold
$10.9M
First sale
Feb 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedFeb 2016 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jocelyn KeyserDirector
  • Jennifer D. RasmussenDirector
  • Carlos GuillemExecutive Officer, Director
  • Harpreet KaurExecutive Officer, Director
  • Dale JonesDirector
  • Nels BergmarkExecutive Officer
Offering amount
$300K
Amount sold
$300K
First sale
Feb 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Renibus Therapeutics: $72 Million Raised To Prevent And Treat Cardio-Renal And Metabolic Diseasespulse2.com · Sep 2023Renibus Therapeutics Receives $47M Financingfinsmes.com · Jul 2023Southlake's Renibus Therapeutics raises $47 million to advance novel drug to Phase 3 trialdallasnews.com · Jul 2023Renibus Therapeutics Raises $33 million Bridge Financing to Advance its Portfolio of Cardiorenal Product Candidates - Renibus Therapeuticsrenibus.com · Nov 2022Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Fundingglobenewswire.com · Feb 2022

Frequently asked questions

How much funding has Renibus Therapeutics raised?
Renibus Therapeutics has disclosed $180.1M raised across 5 of its 6 known rounds.
Where is Renibus Therapeutics headquartered?
Renibus Therapeutics is headquartered in Southlake, US.